FrancophonIA/ELRC3.0 huggingface dataset:
English: The treatment difference (tacrolimus prolonged-release capsules - tacrolimus immediate release capsules) was 3.8% (95% confidence interval [-2.1%, 9.6%]).
Maltese: Id-differenza fit-trattament (tacrolimus kapsuli li jerħu l-mediċina bil-mod - tacrolimus kapsuli li jerħu l-mediċina b'mod immedjat) kienet 3.3% (intervall ta' fiduċja ta' 95% [-5.7%, 12.3%]).
English: coagulopathies, pancytopenia, neutropenia, coagulation and bleeding analyses abnormal rare:
Maltese: koagulopatiji, panċitopenija, newtropenija, analiżi tal-koagulazzjoni u tad-dmija anormali rari:
English: venous thrombosis deep limb, shock, infarction Respiratory, thoracic and mediastinal disorders common:
Maltese: trombożi fil-vini tal-fond fir-riġel, xokk, infart Disturbi respiratorji, toraċiċi u medjastinali komuni:
English: Tacforius 0.5 mg / 1 mg / 3 mg prolonged-release hard capsules Red iron oxide (E172)
Maltese: Tacforius 0.5 mg / 1 mg / 3 mg kapsuli ibsin li jerћu l-mediċina bil-mod: iron oxide aħmar
English: The relationship between tacrolimus trough levels (C24) and systemic exposure (AUC0-24) for tacrolimus prolonged-release capsules is similar to that of tacrolimus immediate release capsules.
Maltese: Ir-relazzjoni bejn l-inqas livelli ta' tacrolimus (C24) u l-espożizzjoni sistemika (AUC0-24) għal tacrolimus kapsuli li jerћu l-mediċina bil-mod tixbaћ ħafna lil dik ta'
English: If PRES is diagnosed, adequate blood pressure and seizure control and immediate discontinuation of systemic tacrolimus is advised.
Maltese: PRES, huwa rakkomandat kontroll adegwat tal-pressjoni tad-demm u tal-aċċessjoni u waqfien minnufih ta' tacrolimus sistemiku.
English: The efficacy and safety of tacrolimus immediate release capsules, ciclosporin and tacrolimus prolonged-release capsules, all in combination with basiliximab antibody induction, MMF and corticosteroids, was compared in 638 de novo kidney transplant recipients.
Maltese: L-effikaċja u s-sigurtà ta' tacrolimus kapsuli li jerħu l-mediċina b'mod immedjat, ciclosporin u tacrolimus kapsuli li jerħu l-mediċina bil-mod, meta ngћataw flimkien ma' induzzjoni tal-antikorp basiliximab, MMF u kortikosterojdi, tqabblu f'638 riċevitur de novo ta' trapjant tal-kliewi.
English: Clinically the following substances have been shown to increase tacrolimus blood levels: Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole, voriconazole and isavuconazole, the macrolide antibiotic erythromycin, HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir) or HCV protease inhibitors (e.g. telaprevir, boceprevir, and the combination of ombitasvir and paritaprevir with ritonavir, when used with and without dasabuvir), the pharmacokinetic enhancer cobicistat, and the tyrosine kinase inhibitors nilotinib and imatinib.
Maltese: Interazzjonijiet qawwija kienu osservati ma' sustanzi antifungali bħalma huma ketoconazole, fluconazole, itraconazole, voriconazole u isavuconazole, l-antibijotiku macrolide erythromycin, inibituri tal-protease tal-HIV (eż. ritonavir nelfinavir, saquinavir) jew inibituri taL-protease tal-HCV
English: Tacrolimus was started as continuous intravenous infusion at a dose of 0.025 mg/kg/day and oral tacrolimus was administered at a dose of 0.15 mg/kg/day with subsequent dose adjustments to target trough levels of 10 to 20 ng/ml.
Maltese: Tacrolimus inbeda bħala infużjoni kontinwa ġol-vini b'doża ta' 0.025 mg/kg/jum u tacrolimus orali ingħata b'doża ta' 0.15 mg/kg/jum b'aġġustamenti wara fid-doża biex jintlaħqu l livelli minimi ta' 10 sa 20 ng/ml.
English: Each capsule of Tacforius 1 mg contains 1 mg of tacrolimus (as monohydrate).
Maltese: Kull kapsula Tacforius 1 mg fiha 1 mg ta' tacrolimus (bħala monohydrate ).
English: Each capsule of Tacforius 5 mg contains 5 mg of tacrolimus (as monohydrate).
Maltese: Kull kapsula Tacforius 5 mg fiha 5 mg ta' tacrolimus (bħala monohydrate ).
English: Tacforius 0.5 mg / 3 mg / 5 mg prolonged-release hard capsules Supplied in blisters or perforated unit-dose blisters containing 10 capsules within a protective foil pouch, including a desiccant.
Maltese: Tacforius 0.5 mg / 3 mg / 5 mg kapsuli ibsin li jerћu l-mediċina bil-mod Disponibbli fil-folji jew bħala kapsuli mifrudin minn ma' xulxin fuq l-istess folja li fiha 10 kapsuli f'qartas protettiv tal-fidda, b'desikkant.
English: The relationship between tacrolimus trough levels (C24) and systemic exposure (AUC0-24) is similar between the two formulations of tacrolimus prolonged-release capsules and tacrolimus immediate release capsules.
Maltese: Ir-relazzjoni li hemm bejn l-inqas livelli ta' tacrolimus (C24) u l-espożizzjoni sistemika (AUC0-24) hija simili bejn iż-żewġ formulazzjonijiet ta' tacrolimus kapsuli li jerћu lmediċina bil-mod u tacrolimus kapsuli li jerћu l-mediċina b'mod immedjat.
English: encephalopathy, central nervous system haemorrhages and cerebrovascular accidents, coma, speech and language abnormalities, paralysis and paresis, amnesia rare:
Maltese: koma, anormalitajiet fil-lingwa u d-diskors, paraliżi u pareżi, amneżija rari:
English: 30 prolonged-release hard capsules 30x1 prolonged-release hard capsules 50 prolonged-release hard capsules 50x1 prolonged-release hard capsules 60 prolonged-release hard capsules 60x1 prolonged-release hard capsules 100 prolonged-release hard capsules 100x1 prolonged-release hard capsules
Maltese: 30 kapsula iebsa li jerћu l-mediċina bil-mod 30x1 kapsula iebsa li jerћu l-mediċina bil-mod 50 kapsula iebsa li jerћu l-mediċina bil-mod 50x1 kapsula iebsa li jerћu l-mediċina bil-mod
English: influenza like illness, feeling jittery, feeling abnormal, multi-organ failure, chest pressure sensation, temperature intolerance rare:
Maltese: diversi organi, sensazzjoni ta' pressjoni fuq is-sider, intolleranza għat-temperatura rari:
English: tinnitus uncommon:
Maltese: indeboliment renali komuni:
English: If abnormalities develop, dose reduction of Tacforius, or change of treatment to another immunosuppressive agent should be considered.
Maltese: F'xi każijiet, kien neċessarju li ttrattament jinqaleb għal immunosoppressjoni alternattiva.
English: respiratory failures, respiratory tract disorders, asthma rare:
Maltese: insuffiċjenza respiratorja, disturbi fil-kanal tan-nifs, ażżma rari:
English: Excretion
Maltese: Assorbiment
English: mobility decreased Renal and urinary disorders very common: renal impairment common:
Maltese: mobilità mnaqqsa Disturbi fil-kliewi u fis-sistema urinarja komuni ħafna:
English: Tacforius is a prolonged-release formulation of tacrolimus resulting in an extended oral absorption profile with an average time to maximum blood concentration (Cmax) of approximately 2 hours (tmax).
Maltese: Tacforius hija formulazzjoni ta' tacrolimus li terħi l-mediċina bil-mod bir-riżultat ta' profil ta' assorbiment orali estiż b'ħin medju sa konċentrazzjoni massima fid-demm (Cmax) ta' bejn wieħed u ieħor sagħtejn (tmax).
English: Tacforius capsules contain lactose.
Maltese: tacrolimus kapsuli li jerћu l-mediċina b'mod immedjat.
English: The treatment difference (tacrolimus prolonged-release capsules - tacrolimus immediate release capsules) was 3.3% (95% confidence interval [-5.7%, 12.3%]).The 12-month patient survival rates were 89.2% for tacrolimus prolongedrelease capsules and 90.8% for tacrolimus immediate release capsules; in the tacrolimus prolongedrelease capsules arm 25 patients died (14 female, 11 male) and in the tacrolimus immediate release capsules arm 24 patients died (5 female, 19 male).
Maltese: 89.2% tal-pazjenti li ћadu tacrolimus kapsuli li jerħu l-mediċina bil-mod u 90.8% tal-pazjenti li ћadu tacrolimus kapsuli li jerħu l-mediċina b'mod immedjat għexu; fil-fergћa ta' tacrolimus kapsuli li jerħu l-mediċina bil-mod 25 pazjent mietu (14 nisa, 11 irġiel) u fil-fergħa ta' tacrolimus kapsuli li jerħu l mediċina b'mod immedjat 24 pazjent mietu (5 nisa, 19 irġiel).
English: Uncommon side effects (may affect up to 1 in 100 people) - Changes in blood clotting, reduction in the number of all types of blood cells (seen in blood tests) - Dehydration, inability to urinate - Abnormal blood test results: reduced protein or sugar, increased phosphate, increase of the enzyme lactate dehydrogenase - Coma, bleeding in the brain, stroke, paralysis, brain disorder, speech and language abnormalities, memory problems - Clouding of the eye lens, impaired hearing - Irregular heartbeat, stop of heartbeat, reduced performance of your heart, disorder of the heart muscle, enlargement of the heart muscle, stronger heartbeat, abnormal ECG, heart rate and pulse abnormal - Blood clot in a vein of a limb, shock - Difficulties in breathing, respiratory tract disorders, asthma - Obstruction of the gut, increased blood level of the enzyme amylase, reflux of stomach content in your throat, delayed emptying of the stomach - Inflammation of the skin, burning sensation in the sunlight - Joint disorders - Painful menstruation and abnormal menstrual bleeding - Multiple organ failure, flu-like illness, increased sensitivity to heat and cold, feeling of pressure on your chest, jittery or abnormal feeling, weight loss
Maltese: - Bidla fit-tagħqid tad-demm, tnaqqis fin-numru tat-tipi kollha ta' ċelluli tad-demm (li jidhru f'testijiet tad-demm) - Deidratazzjoni (nixfa), ma tistax tgħaddi l-awrina - Riżultati ta' testijiet tad-demm li mhumiex normali: tnaqqis ta' proteini jew zokkor, żieda ta' phosphate, żieda fl-enzima lactate dehydrogenase - Koma, emorraġija fil-moħħ, puplesija, paraliżi, disturb fil-moħħ, anormalitajiet fil-kliem u fillingwa, problemi ta' memorja
English: hearing impaired Cardiac disorders common:
Maltese: Disturbi gastro-intestinali komuni ħafna:
English: Tubing, syringes and other equipment used to prepare a suspension of Tacforius capsule contents must not contain PVC.
Maltese: Tubi, siringi u apparat ieħor li jintuża biex titlesta suspensjoni tal-kontenut tal-kapsula ta' Tacforius m'gћandux ikun fihom PVC.
English: CYP3A4 inducers potentially leading to decreased tacrolimus blood levels
Maltese: Inibituri ta' CYP3A4 li jistgћu jżidu l-livelli fid-demm ta' tacrolimus
English: - if you are allergic to sirolimus or to any macrolide-antibiotic (e.g. erythromycin, clarithromycin, josamycin).
Maltese: - jekk int allerġiku gћal sirolimus jew gћal kwalunkwe antibijotiku macrolide (eż. erythromycin,
English: Tacforius 0.5 mg prolonged-release capsules Tacforius 1 mg prolonged-release capsules Tacforius 3 mg prolonged-release capsules Tacforius 5 mg prolonged-release capsules tacrolimus
Maltese: Tacforius 1 mg kapsuli li jerћu l-mediċina bil-mod Tacforius 3 mg kapsuli li jerћu l-mediċina bil-mod Tacforius 5 mg kapsuli li jerћu l-mediċina bil-mod tacrolimus
English: Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1.
Maltese: Sensittività eċċessiva għas-sustanza attiva jew għal kwalunkwe sustanza mhux attiva elenkata fissezzjoni 6.1.
English: High potassium intake or potassium-sparing diuretics should be avoided (see section 4.5).
Maltese: Tilqim ħaj attenwat għandu jiġi evitat (ara sezzjoni 4.4).
English: Once daily.
Maltese: 30 xahar.
English: The 12-month patient survival rates were 96.9% for tacrolimus prolonged-release capsules and 97.5% for tacrolimus immediate release capsules; in the tacrolimus prolonged-release capsules arm 10 patients died (3 female, 7 male) and in the tacrolimus immediate release capsules arm 8 patients died (3 female, 5 male).
Maltese: Wara 12-il xahar mit-trapjant, 96.9% tal-pazjenti li ћadu tacrolimus kapsuli li jerħu l mediċina bil-mod u 97.5% tal-pazjenti li ћadu tacrolimus kapsuli li jerħu l-mediċina b'mod immedjat għexu; fil-grupp ta' tacrolimus kapsuli li jerħu l-mediċina bil-mod 10 pazjenti mietu (3 nisa, 7 irġiel) u fil-grupp ta' tacrolimus kapsuli li jerħu l-mediċina b'mod immedjat 8 pazjenti mietu (3 nisa, 5 irġiel).
English: Caution should be exercised in patients with risk factors for QT prolongation, including patients with a personal or family history of QT prolongation, congestive heart failure, bradyarrhythmias and electrolyte abnormalities.
Maltese: Għandu jkun hemm attenzjoni f'pazjenti li għandhom fatturi ta' riskju għal titwil ta' QT, inkluż pazjenti bi storja personali jew tal-familja ta' titwil ta' QT, insuffiċjenza konġestiva tal-qalb, bradiarritmija u anormalitajiet fl-elettroliti .
English: Tacforius is not recommended for use in children below 18 years due to limited data on safety and/or efficacy.
Maltese: Tacforius mhuwiex rakkomandat gћall-użu fit-tfal taћt 18-il sena minħabba data limitata dwar is sigurtà u/jew l-effikaċja.
English: Active substances which interfere with mycophenolic acid's enterohepatic cycle have potential to reduce the plasma level and efficacy of mycophenolic acid.
Maltese: Sustanzi attivi li jinterferixxu maċ-ċiklu enterepatiku ta' mycophenolic acid għandhom il-potenzjal li jnaqqsu llivell ta' mycophenolic acid fil-plażma u l-effikaċja tiegħu.
English: Effect of tacrolimus on the metabolism of other medicinal products
Maltese: L-effett ta' tacrolimus fuq il-metaboliżmu ta' prodotti mediċinali oħra
English: Each capsule contains 5 mg tacrolimus (as monohydrate).
Maltese: Kull kapsula fiha 5 mg ta' tacrolimus (bħala monohydrate).
English: Treatment of allograft rejection
Maltese: TAL-PRODOTT MEDIĊINALI
English: In particular, you should tell your doctor if you are taking or have recently taken medicines like: - antifungal medicines and antibiotics, particularly so-called macrolide antibiotics, used to treat infections e.g. ketoconazole, fluconazole, itraconazole, voriconazole, clotrimazole, and isavuconazole, erythromycin, clarithromycin, josamycin, and rifampicin - HIV protease inhibitors (e.g ritonavir, nelfinavir, saquinavir), the booster medicine cobicistat,
Maltese: B'mod partikolari għandek tgħid lit-tabib tiegħek jekk tkun qed tieħu jew jekk reċentement ħadt xi mediċini bħal: - mediċini antifungali u antibijotiċi, partikolarment dawk imsejħa antibijotiċi makrolidi, li jintużaw kontra l-infezzjonijiet eż. ketoconazole, fluconazole, itraconazole, voriconazole, clotrimazole, u isavuconazole, erythromycin, clarithromycin, josamycin, u rifampicin - inibituri tal-protease tal-HIV (eż. ritonavir, nelfinavir, saquinavir), il-mediċina booster cobicistat, u pilloli ta' kombinazzjoni, li jintużaw gћat-trattament tal-infezzjoni tal-HIV - inibituri tal-protease tal-HCV (eż. telaprevir, boceprevir, u l-kombinazzjoni ombitasvir/paritaprevir/ritonavir bi jew mingħajr dasabuvir), li jintuzaw biex jikkuraw infezzjoni tal-epatite Ċ
English: Increased doses of tacrolimus, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes.
Maltese: korsijiet qosra ta' antikorpi mono-/poliklonali kollha ntużaw biex jikkontrollaw episodji ta' rifjut.
English: Pain in extremity has been described in a number of published case reports as part of CalcineurinInhibitor Induced Pain Syndrome (CIPS).
Maltese: Sindrome ta' Uġigħ Ikkaġunat minn Inibitur ta' Calcineurin (CIPS - Calcineurin-Inhibitor Induced
English: The efficacy and safety of tacrolimus prolonged-release capsules and tacrolimus immediate release capsules, both in combination with mycophenolate mofetil (MMF) and corticosteroids, was compared in 667 de novo kidney transplant recipients.
Maltese: L-effikaċja u s-sigurtà ta' tacrolimus kapsuli li jerħu l-mediċina bil-mod u tacrolimus kapsuli li jerħu lmediċina b'mod immedjat, meta ngћataw flimkien ma' mycophenolate mofetil (MMF) u kortikosterojdi, tqabblu f'667 riċevitur de novo ta' trapjant tal-kliewi.
English: Tacforius 0.5 mg prolonged-release hard capsules Hard gelatin capsules imprinted with “TR” on the light yellow capsule cap and “0.5 mg” on the light orange capsule body.
Maltese: Tacforius 0.5 mg kapsuli ibsin li jerћu l-mediċina bil-mod Kapsuli ibsin tal-ġelatina stampati b'“TR” fuq l-għatu isfar ċar tal-kapsula u bi “0.5 mg” fuq il-parti prinċipali oranġjo ċara tal-kapsula.
English: Dose reduction may be necessary in patients with severe liver impairment (see section 4.2).
Maltese: F'pazjenti li jkollhom indeboliment sever tal-fwied jista' jkun meħtieġ tnaqqis fid-doża (ara sezzjoni 4.2).
English: In systemic circulation only one of the inactive metabolites is present at low concentrations.
Maltese: Fiċ-ċirkolazzjoni sistemika hemm wieħed biss mill-metaboliti inattivi, b'konċentrazzjoni baxxa.
English: Each capsule contains 0.5 mg tacrolimus (as monohydrate).
Maltese: Kull kapsula fiha 0.5 mg ta' tacrolimus (bħala monohydrate).
English: bile duct disorders, hepatocellular damage and hepatitis, cholestasis and jaundice rare:
Maltese: disturbi fil-kanal tal-marrara, ħsara epatoċellulari u epatite, kolestasi u suffejra rari:
English: Tacforius therapy should commence at a dose of 0.20 - 0.30 mg/kg/day administered once daily in the morning.
Maltese: Terapija b'Tacforius għandha tibda b'doża ta' 0.20 - 0.30 mg/kg/jum mogħtija darba kuljum filgħodu.
English: Gelatin capsules imprinted with “TR” on the light orange capsule cap and “3 mg” on the light orange capsule body.
Maltese: Kapsuli ibsin tal-ġelatina stampati b'“TR” fuq l-għatu oranġjo ċar tal-kapsula u bi “3 mg” fuq il-parti prinċipali oranġjo ċara tal-kapsula.
English: and combination tablets, used to treat HIV infection - HCV protease inhibitors (e.g. telaprevir, boceprevir and the combination ombitasvir/paritaprevir/ritonavir with or without dasabuvir), used to treat hepatitis C infection - nilotinib and imatinib (used to treat certain cancers) - mycophenolic acid, used to suppress the immune system to prevent transplant rejection - medicines for stomach ulcer and acid reflux (e.g. omeprazole, lansoprazole or cimetidine) - antiemetics, used to treat nausea and vomiting (e.g. metoclopramide) - cisapride or the antacid magnesium-aluminium-hydroxide, used to treat heartburn - the contraceptive pill or other hormone treatments with ethinylestradiol, hormone treatments with danazol - medicines used to treat high blood pressure or heart problems (e.g. nifedipine, nicardipine,
Maltese: It-tabib tiegħek jeħtieġ ukoll ikun jaf jekk, waqt li qed tieħu Tacforius, intix qed tieħu wkoll supplimenti ta' potassium jew ċerti dijuretiċi li jintużaw gћall-insuffiċjenza tal-qalb, pressjoni gћolja u mard tal-kliewi (eż. amiloride, triamterene jew spironolactone), mediċini anti-infjammatorji mhux sterojdi (NSAIDs - non-steroidal anti-inflammatory drugs eż. ibuprofen) li jintużaw gћad-deni,
English: Tacrolimus was started as continuous intravenous infusion at a dose of 0.05 mg/kg/day and oral tacrolimus was administered at a dose of 0.1 to 0.3 mg/kg/day with subsequent dose adjustments to target trough levels of 12 to 15 ng/ml.
Maltese: Tacrolimus inbeda bħala infużjoni kontinwa fil-vini b'doża ta' 0.05 mg/kg/jum u tacrolimus orali ingħata b'doża ta' 0.1 sa 0.3 mg/kg/jum b'aġġustamenti wara fid doża biex jilħqu l-livelli minimi ta' 12 sa 15 ng/ml.
English: renal failure, renal failure acute, nephropathy toxic, renal tubular necrosis, urinary abnormalities, oliguria, bladder and urethral symptoms uncommon:
Maltese: insuffiċjenza renali, insuffiċjenza renali akuta, nefropatija tossika, nekrosi tubulari tal-kliewi, anormalitajiet urinarji, oligurja, sintomi tal-bużżieqa u tal-kanal talawrina mhux komuni:
English: Packs of 30, 50, 60 and 100 prolonged-release capsules are available in blisters and packs of 30x1, 50x1, 60x1 and 100x1 prolonged-release capsules are available in perforated unit-dose blisters.
Maltese: Pakketti ta' 30, 50, 60 u 100 kapsula li terħi l-mediċina bil mod huma disponibbli f'folji u pakketti ta' 30x1, 50x1, 60x1 u 100x1 kapsula li terħi l-mediċina bilmod huma disponibbli mifrudin minn xulxin fuq l-istess folja.
English: Tacforius 3 mg prolonged-release hard capsules Each prolonged-release hard capsule contains 3 mg tacrolimus (as monohydrate).
Maltese: Tacforius 3 mg kapsuli ibsin li jerћu l-mediċina bil-mod Kull kapsula iebsa li terћi l-mediċina bil-mod fiha 3 mg tacrolimus (bħala monohydrate).
English: The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of cytokine genes.
Maltese: Il-kumpless FKBP12tacrolimus speċifikament u kompetittivament jingħaqqad ma' u jinibixxi calcineurin, li jwassal għall inibizzjoni tal-mogħdijiet tat-transduzzjoni tas-sinjal taċ-ċellula T li huma dipendenti fuq il-calcium, u b'dan il-mod jipprevjeni t-transkrizzjoni ta' sett ta' ġene ta' ċitokini diskreti.
English: Stevens Johnson syndrome Musculoskeletal and connective tissue disorders common:
Maltese: Disturbi muskolu-skeletriċi u tat-tessuti konnettivi komuni:
English: Each capsule contains 3 mg tacrolimus (as monohydrate).
Maltese: Kull kapsula fiha 3 mg ta' tacrolimus (bħala monohydrate).
English: Pregnancy and breast-feeding
Maltese: Trapjant tal-frixa
English: 12-month graft survival was 91.5% for tacrolimus prolonged-release capsules and 92.8% for tacrolimus immediate release capsules.
Maltese: Wara 12-il xahar mit-trapjant, kien hemm sopravivenza tat-trapjant ta' 91.5% gћal tacrolimus kapsuli li jerħu l-mediċina bil-mod u 92.8% gћal tacrolimus kapsuli li jerħu l-mediċina b'mod immedjat.
English: As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene, or spironolactone) should be avoided (see section 4.4).
Maltese: Billi l-kura ta' tacrolimus tista' tkun assoċjata mal-iperkalimja, jew tista' żżid l-iperkalimja eżistenti minn qabel, għandu jiġi evitat it-teħid ta' ammont kbir ta' potassium, jew dijuretiċi potassium-sparing (eż. amiloride, triamterene, jew spironolactone) (ara sezzjoni 4.4).
English: Each capsule contains 1 mg tacrolimus (as monohydrate).
Maltese: Kull kapsula fiha 1 mg ta' tacrolimus (bħala monohydrate).
English: In healthy subjects, the mean half-life in whole blood is approximately 43 hours.
Maltese: F'individwi f'saħħithom, il-medja tal-half life fid-demm sħiħ hi bejn wieħed u ieħor ta' 43 siegħa.
English: Tacforius 1 mg prolonged-release hard capsules Each prolonged-release hard capsule contains 1 mg tacrolimus (as monohydrate).
Maltese: Tacforius 1 mg kapsuli ibsin li jerћu l-mediċina bil-mod Kull kapsula iebsa li terћi l-mediċina bil-mod fiha 1 mg tacrolimus (bħala monohydrate).
English: arthralgia, back pain, muscle spasms, pain in extremity uncommon:
Maltese: artralgja, uġigħ fid-dahar,spażmi muskolari, uġigħ f'estremità mhux komuni:
English: In adult liver, kidney and heart transplant patients, values of 4.1 l/h, 6.7 l/h and 3.9 l/h, respectively, have been observed.
Maltese: Fi trapjanti tal fwied, tal-kliewi u tal-qalb f'pazjenti adulti kienu osservati rispettivament il-valuri ta' 4.1 l/siegħa,
English: Tacforius 5 mg prolonged-release hard capsules Each prolonged-release hard capsule contains 5 mg tacrolimus (as monohydrate).
Maltese: Tacforius 5 mg kapsuli ibsin li jerћu l-mediċina bil-mod Kull kapsula iebsa li terћi l-mediċina bil-mod fiha 5 mg tacrolimus (bħala monohydrate).
English: Lansoprazole and ciclosporin may potentially inhibit CYP3A4-mediated metabolism of tacrolimus and thereby increase tacrolimus whole blood concentrations.
Maltese: Lansoprazole u ciclosporin jista' jkun li potenzjalment jinibixxu l-metaboliżmu medjat minn CYP3A4
English: diltiazem and verapamil) - anti-arrhythmic medicines (amiodarone) used to control arrhythmia (uneven beating of the heart) - medicines known as “statins” used to treat elevated cholesterol and triglycerides - phenytoin or phenobarbital, used to treat epilepsy
Maltese: - mediċini kontra l-arritmija (amiodarone) użati għall-kontroll tal-arritmija (taħbit irregolari tal qalb)
English: The interim analysis of a recent multicentre study using oral tacrolimus immediate release capsules discussed 110 patients who underwent 1:1 randomisation to either tacrolimus or ciclosporin.
Maltese: L-analiżi interim ta' studju reċenti minn diversi ċentri li wżaw tacrolimus kapsuli li jerħu l-mediċina b'mod immedjat orali kien dwar 110 pazjenti li kienu randomised 1:1 biex jingħataw tacrolimus jew ciclosporin.